Department of Obstetrics and Gynecology, Fatmawati Central General Hospital, Jakarta, Indonesia.
Department of Obstetrics and Gynecology, Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia.
Asian Pac J Cancer Prev. 2024 Feb 1;25(2):513-519. doi: 10.31557/APJCP.2024.25.2.513.
Ovarian cancer is one of the most common cancers with a high mortality rate worldwide. Despite optimal surgical therapy and chemotherapy, recurrence is still common. Cancer stem cells expressing CD44 and CD24 are thought to be contributing factors in recurrence.
A cohort retrospective study with survival analysis was carried out on advanced ovarian cancer patients who underwent optimal debulking surgery followed by 6 cycles of chemotherapy at Cipto Mangunkusumo General Hospital and Fatmawati General Hospital from January 2019 to March 2023. Immunohistochemical examination was performed on tumor tissue with CD44 and CD24 expression were assessed using the H-Score method then determined the cut off-point expression level using the ROC curve. Furthermore, the relationship between these expression levels with the disease-free survival was assessed using the survival curve.
There were 48 subjects who were included in the study. There were high expression levels of CD44 in 47.9% and CD24 in 50% of cases. High CD44 expression had mean and median survival of 13.2 ± 1.8 and 11 months (HR 5.05, 95% CI 1.84- 13.85). High CD24 expression had mean and median survival of 13.5 ± 2.4 and 7 months (HR 7.73, 95% CI 2.58 - 23.15). The combination of the two high expressions had mean and median survival of 10.44 ± 1.88 and 7 months.
High expression of CD44 and CD24 will shorten the disease-free survival of patients with advanced ovarian cancer.
卵巢癌是全球死亡率较高的最常见癌症之一。尽管进行了最佳的手术治疗和化疗，但其复发仍然较为常见。表达 CD44 和 CD24 的癌症干细胞被认为是导致复发的因素之一。
本研究为一项回顾性队列研究，对 2019 年 1 月至 2023 年 3 月期间在 Cipto Mangunkusumo 综合医院和 Fatmawati 综合医院接受最佳减瘤手术及 6 个周期化疗的晚期卵巢癌患者进行生存分析。对肿瘤组织进行 CD44 和 CD24 表达的免疫组织化学检查，采用 H 评分法评估 CD44 和 CD24 的表达水平，并用 ROC 曲线确定截断点表达水平。进一步采用生存曲线评估这些表达水平与无病生存期的关系。
本研究共纳入 48 例患者。CD44 高表达者占 47.9%，CD24 高表达者占 50.0%。CD44 高表达者的平均和中位生存时间分别为 13.2±1.8 个月和 11 个月（HR 5.05，95%CI 1.84-13.85）。CD24 高表达者的平均和中位生存时间分别为 13.5±2.4 个月和 7 个月（HR 7.73，95%CI 2.58-23.15）。两种标志物均高表达者的平均和中位生存时间分别为 10.44±1.88 个月和 7 个月。
CD44 和 CD24 的高表达会缩短晚期卵巢癌患者的无病生存期。
